In order to gain an orphan asset with near-term revenue potential, Jazz Pharmaceuticals has agreed to pay a significant premium to acquire Celator Pharmaceuticals for approximately US$1.5 B in cash. The key driver of the deal is Vyxeos™ (cytarabine:daunorubicin), an optimised encapsulated formulation of two existing chemotherapy drugs developed using Celator’s CombiPlex® platform. Vyxeos prolonged the life of elderly patients with secondary acute myeloid leukaemia by 3.61 months versus the standard of care in a Phase III trial.